To study the association between DISC1 RNA expression levels and cardiac function in patients with schizophrenia.
Potential participants interested in the study will be screened for eligibility. Those who meet the eligibility criteria will be informed about the study, the expected investigations and its potential risks. All participants giving written informed consent will be enrolled into the study. Participants will be interviewed, given questionnaires, have blood and/or skin samples and clinical parameters taken. Cardiac function parameters will be measured using electrocardiography, echocardiography and magnetic resonance imaging.
Study Type
OBSERVATIONAL
Enrollment
120
ultrasound assessment of heart structure, volume and function
MRI assessment of heart structure, volume, function and tissue characteristics
Assessment of cardiac rhythm and electrical activity
Norwegian University of Science and Technology
Trondheim, Norway
St Olavs Hospital, Trondheim University Hospital
Trondheim, Norway
Left Ventricular Ejection Fraction (LVEF) measured by 2D Echocardiography
Left ventricular ejection fraction, LVEF will be reported in percentage (%) and obtained using Simpson's biplane method from 2D echocardiography.
Time frame: Baseline
Left Ventricular Ejection Fraction (LVEF) measured by 3D Echocardiography
Left ventricular ejection fraction, LVEF will be reported in percentage (%) and obtained using 3D echocardiography
Time frame: Baseline
DISC1 mRNA quantification
Measured from blood samples and reported as fold change
Time frame: Baseline
Levels of high sensitive-CRP
Levels of HS-CRP mg/L
Time frame: Baseline
Levels of CK-MB
Levels of CK-MB is reported in µg/L
Time frame: Baseline
Levels of Troponin T
Levels of Troponin T is reported in ng/L
Time frame: Baseline
Levels of Troponin I
Levels of Troponin I is reported in ng/L
Time frame: Baseline
Normalized Left Ventricular End-Diastolic Volume (LV EDV), echocardiographic parameter
LV EDV in milliliters (mL) will be normalized against body surface area (BSA) in m\^2 to report LV EDV normalized by BSA in mL/m\^2.
Time frame: Baseline
Normalized Right Ventricular End-Diastolic Volume (RV EDV), echocardiographic parameter
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
To measure DISC1 mRNA expression and other potential biomarkers
RV EDV in mL will be normalized against body surface area (BSA) in m\^2 to report RV EDV normalized by BSA in mL/m\^2.
Time frame: Baseline
Normalized left Ventricular End-Systolic Volume (LV ESV), echocardiographic parameter
LV ESV in mL will be normalized against body surface area (BSA) in m\^2 to report LV ESV normalized by BSA in mL/m\^2.
Time frame: Baseline
Normalized Right Ventricular End-Systolic Volume (RV ESV), echocardiographic parameter
RV ESV in mL will be normalized against body surface area (BSA) in m\^2 to report RV ESV normalized by BSA in mL/m\^2.
Time frame: Baseline
Left ventricular mass measured by echocardiography
Left ventricular mass in grams (g) will be normalized against BSA in m\^2 and reported as g/m \^2
Time frame: Baseline
Left ventricular septal thickness, left ventricular posterior wall thickness and right ventricular wall thickness measured by echocardiography
Left ventricular septal thickness, left ventricular posterior wall thickness and right ventricular wall thickness will be reported in centimeters (cm)
Time frame: Baseline
Fractional shortening measured by echocardiography
Fractional shortening will be reported as a percentage (%)
Time frame: Baseline
Global longitudinal strain (GLS), echocardiographic parameter
GLS(%) = (MLs - MLd)/MLd, where MLs is myocardial length at end-systole and MLd is the myocardial length at end-diastole. GLS will be reported in precentage (%)
Time frame: Baseline
TAPSE echocardiographic parameter of right ventricular longitudinal systolic function
TAPSE will be reported in millimeters (mm)
Time frame: baseline
Echocardiographic parameter MPI, Myocardial performance index
MPI is a unitless index derived from the sum of the isovolumic relaxation time (IVRT) and the isovolumic contraction time (IVCT) in milliseconds (ms) divided by the ejection time interval in (ms).
Time frame: Baseline
Echocardiographic parameter Mitral E/A ratio
Mitral E/A ratio is derived from the ratio of the E wave velocity to the A wave velocity
Time frame: Baseline
Echocardiography parameter of peak E velocity
peak E velocity is reported in cm/s
Time frame: Baseline
Echocardiography parameter of E wave deceleration time
E wave deceleration time is reported in milliseconds (ms)
Time frame: Baseline
Echocardiography parameter of ratio of E/e'
The E/e' ratio is derived from the E wave velocity to the e' velocity
Time frame: Baseline
Echocardiographic parameters septal e' and lateral e' velocities
Septal e' and lateral e' velocities are reported as cm/s
Time frame: Baseline
Echocardiographic parameter LAVI, left atrial volume indexed
LAVI is reported in mL/m\^2 and is the volume (mL) of the left atrium indexed against the BSA in m\^2.
Time frame: Baseline
Echocardiographic parameter TRpV, Tricuspid Regurgitation peak Velocity
TRpV is reported in m/s
Time frame: Baseline
Echocardiographic parameter, S wave velocity
S wave velocity is the peak systolic velocity of the tricuspid annulus and is reported in cm/s
Time frame: Baseline
Echocardiographic parameter, Indexed LV and RV stroke volumes
Indexed LV stroke volume and Indexed RV stroke volume will be reported in mL/m\^2 by by indexing the volumes (mL) to BSA (m\^2)
Time frame: Baseline
Levels of NT-proBNP
Levels of NT-proBNP from blood samples will be reported in ng/L
Time frame: Baseline
Levels of IGF1
Levels of IGF1 from blood samples will be reported in nmol/L
Time frame: Baseline
Levels of ANP
Levels of ANP from blood samples will be reported in pg/mL
Time frame: Baseline
Levels of BDNF, brain derived neurotrophic factor
Levels of BDNF from blood samples will be reported in ng/mL
Time frame: Baseline
Levels of Tumor Necrosis Factor alpha
Levels of Tumor Necrosis Factor alpha from blood samples will be reported in pg/mL
Time frame: Baseline
Levels of Transforming Growth Factor Beta
Levels of Transforming Growth Factor Beta from blood samples will be reported in ng/mL
Time frame: Baseline
Levels of cardiac Myosin-Binding Protein C
Levels of cardiac Myosin-Binding Protein C from blood samples will be reported in ng/L
Time frame: Baseline
Interleukin levels
Interleukin levels from blood sample will be reported as pg/mL
Time frame: Baseline
native T1 time, cardiac MRI
native myocardial T1 relaxation time is reported in milliseconds (ms)
Time frame: Baseline
Indexed LV and RV end-diastolic, end-systolic and stroke volumes, cardiac MRI
Indexed LV and RV end-diastolic, end-systolic and stroke volumes will be reported in mL/m\^2, by indexing the volumes (mL) to BSA (m\^2)
Time frame: Baseline
Indexed LV mass, cardiac MRI
Indexed LV mass will be reported in g/m\^2 by indexing mass (g) to BSA (m\^2)
Time frame: Baseline
LV Ejection Fraction, cardiac MRI
LVEF will be reported in percent (%)
Time frame: Baseline
ECG corrected QT interval
corrected QT interval will be reported in milliseconds (ms)
Time frame: Baseline
Number of participants with and abnormal ECG
Number of participants with an abnormal ECG will be reported in %
Time frame: Baseline
Number of participants with abnormal liver function
Number of participants with abnormal liver function will be reported as %
Time frame: Baseline
Number of participants with abnormal kidney function
Number of participants with abnormal kidney function will be reported as %
Time frame: Baseline
Number of participants with abnormal thyroid function
Number of participants with abnormal thyroid function will be reported as %
Time frame: Baseline
Number of participants with low Vitamin D levels
Number of participants with low Vitamin D levels will be reported as %
Time frame: Baseline
Incidence of cardiovascular disease or mortality as registered in a health registry on follow up
Extraction of information from the cardiovascular disease registry and deaths registry between 10 - 15 years from the start of the study to determine incidence of cardiovascular disease outcomes for the study cohort
Time frame: Within 15 years from start of study
Triglyceride levels
Triglyceride will be reported in mmol/L
Time frame: Baseline
High-density lipoprotein, HDL-cholesterol levels
HDL-cholesterol levels will be reported in mmol/L
Time frame: Baseline
Low-density lipoprotein, LDL-cholesterol levels
LDL-cholesterol levels will be reported in mmol/L
Time frame: Baseline
Fasting glucose levels
Fasting glucose levels will be reported in mmol/L
Time frame: Baseline
Glycated Hemoglobin (HbA1c) levels
HbA1C will be reported in mmol/mol
Time frame: Baseline
Heart rate measured on ECG
Heart rate measured on 12 lead ECG will be reported in beats per minute.
Time frame: Baseline
Systolic Blood Pressure
Systolic Blood Pressure will be reported as mmHg
Time frame: Baseline
Diastolic Blood Pressure
Diastolic Blood Pressure will be reported as mmHg
Time frame: Baseline
Lipoprotein a
Lipoprotein a levels will be reported in mg/L
Time frame: Baseline
Magnesium levels
Magnesium levels will be reported as mmol/L
Time frame: Baseline
Calcium levels
Calcium levels will be reported as mmol/L
Time frame: Baseline
Sodium levels
Sodium levels will be reported as mmol/L
Time frame: Baseline
Potassium levels
Potassium levels will be reported as mmol/L
Time frame: Baseline